$49.50 Million in Sales Expected for Beigene Ltd (BGNE) This Quarter
Analysts expect Beigene Ltd (NASDAQ:BGNE) to report sales of $49.50 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Beigene’s earnings, with estimates ranging from $44.00 million to $55.00 million. Beigene reported sales of $52.80 million in the same quarter last year, which indicates a negative year over year growth rate of 6.3%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Beigene will report full year sales of $250.54 million for the current fiscal year, with estimates ranging from $151.00 million to $446.45 million. For the next financial year, analysts anticipate that the business will post sales of $341.47 million, with estimates ranging from $200.00 million to $538.49 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Beigene.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($2.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.15) by $0.34. Beigene had a negative return on equity of 44.53% and a negative net margin of 302.58%. The firm had revenue of $77.83 million for the quarter, compared to the consensus estimate of $55.79 million. During the same quarter in the prior year, the business earned ($2.03) EPS. The business’s revenue for the quarter was up 139.2% compared to the same quarter last year.
In related news, CEO John Oyler sold 25,499 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $151.73, for a total value of $3,868,963.27. Following the completion of the sale, the chief executive officer now owns 17,298,245 shares in the company, valued at approximately $2,624,662,713.85. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Xiaodong Wang sold 5,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $146.82, for a total transaction of $734,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 77,476 shares of company stock valued at $11,038,087 in the last quarter. Corporate insiders own 13.30% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its position in shares of Beigene by 1.9% in the 4th quarter. Jennison Associates LLC now owns 4,513 shares of the company’s stock valued at $633,000 after buying an additional 86 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its position in shares of Beigene by 4.8% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 2,753 shares of the company’s stock valued at $363,000 after buying an additional 127 shares in the last quarter. Comerica Bank increased its position in shares of Beigene by 3.5% in the 1st quarter. Comerica Bank now owns 4,365 shares of the company’s stock valued at $638,000 after buying an additional 146 shares in the last quarter. Neuburgh Advisers LLC bought a new stake in shares of Beigene in the 4th quarter valued at $27,000. Finally, Quadrant Capital Group LLC increased its position in shares of Beigene by 131.8% in the 1st quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock valued at $47,000 after buying an additional 207 shares in the last quarter. Institutional investors and hedge funds own 79.83% of the company’s stock.
NASDAQ:BGNE traded down $10.76 during trading hours on Monday, hitting $123.46. 352,800 shares of the stock were exchanged, compared to its average volume of 346,347. Beigene has a twelve month low of $105.19 and a twelve month high of $220.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.82 and a current ratio of 7.89. The company has a market cap of $8.03 billion, a price-to-earnings ratio of -10.16 and a beta of 1.07.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Featured Article: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.